89bio, Inc. Common Stock
Symbol: ETNB (NASDAQ)
9.16
▼ (-3.58%) -0.340
Company Description:
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Key Stats
- Today's Open: $9.11
- Today's High: $9.195
- Today's Low: $9.08
- Today's Volume: 652.08K
- Yesterday Close: $9.5
- Yesterday High: $9.76
- Yesterday Low: $9.31
- Yesterday Volume: 1.08M
- Last Min Volume: 181
- Last Min High: $9.16
- Last Min Low: $9.16
- Last Min VWAP: $9.16
Company Profile
- Name: 89bio, Inc. Common Stock
- Website: https://www.89bio.com
- Listed Date: 2019-11-11
- Location: SAN FRANCISCO, CA
- Market Status: Active
- CIK Number: 0001785173
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.34B
- Round Lot: 100
- Outstanding Shares: 145.98M
- Asset Type: CS
RECENT FILINGS FOR ETNB
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-07-29 | SCHEDULE 13G | View |
| 2025-07-17 | 4 | View |
| 2025-07-15 | 144 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-05-30 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
| 2025-05-02 | SCHEDULE 13G/A | View |
| 2025-05-02 | 10-Q | View |
| 2025-05-01 | 8-K | View |
| 2025-04-17 | 4 | View |
| 2025-04-15 | ARS | View |
| 2025-04-15 | DEFA14A | View |
| 2025-04-15 | DEF 14A | View |
| 2025-04-15 | 144 | View |
| 2025-04-09 | 8-K | View |
| 2025-03-03 | SCHEDULE 13D/A | View |
Latest News on ETNB